바로가기
메인메뉴로 바로가기
콘텐츠 바로가기
하단메뉴로 바로가기
패밀리사이트 바로가기


진료과

  • 연세암병원-종양내과, 두경부암센터, 식도암센터, 폐암센터

전문진료분야

  • <종양내과> 폐암, 두경부암, 식도암, 원발미상암, 항암약물치료, 신약치료

진료시간표

인터넷진료예약 ...
의사시간표
진료시간
오전 암병원 암병원 암병원
오후 암병원 암병원 암병원

교육 및 임상 경력

  • 2005-2006  세브란스병원  인턴  수료
  • 2006-2010  세브란스병원  전공의  수료
  • 2010-2013  공중보건의  (강화병원  내과  과장)
  • 2013-2014  세브란스병원  종양내과  강사
  • 2014-2015  서울대학교  보라매병원  강사
  • 2015-2016  MSD/Merck  oncology  의학부  이사  (medical  advisor)
  • 2016-현  재  연세의료원  연세암병원  종양내과  임상조교수

학술관련경력

  • 대한 내과학회
  • 대한 종양내과학회 (Korean Association for Clinical Oncology)
  • 대한 암학회 (Korean Cancer Association)
  • 대한 항암요법 연구회 (Korean Cancer Study Group)
  • 대한 소화기내시경학회
  • 한국 제약의학회 (The Korean Society of Pharmaceutical Medicine)
  • 대한 폐암학회 (Korean Association for Lung Cancer)
  • 대한 항암요법 연구회, 폐암분과
  • 대한 항암요법 연구회, 두경부식도암 분과
  • 세계 폐암학회 (The International Association for the Study of Lung Cancer)

주요 관심분야

  • '폐암, 식도암, 두경부암'의 항암약물치료, 면역항암제, 표적치료제 및 임상신약치료

학력사항

  • 2005 연세대학교 의과대학 졸업
  • 2015 연세대학교 의과대학 석사

논문

  • Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat. 2009 Jun;41(2):67-72
  • Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. Cancer Res Treat. 2009 Dec;41(4):196-204.
  • Prognosis of pN3 stage gastric cancer. Cancer Res Treat. 2009 Jun;41(2):73-9.
  • Clinical value of ezrin expression in primary osteosarcoma. Cancer Res Treat. 2009 Sep;41(3):138-44.
  • Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. Cancer Chemother Pharmacol. 2010 Sep;66(4):797-805.
  • Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Oncology. 2011;80(5-6):395-405.
  • Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. Cancer Chemother Pharmacol. 2014 Oct;74(4):799-808.
  • PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Sci Rep. 2016 Nov 14;6:36956.
  • Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma. Ann Oncol. 2017 Jun 1;28(6):1250-1259.
  • Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis. Oncotarget. 2017 May 10. doi: 10.18632/oncotarget.
  • Povidone-iodine for the management of oral mucositis during cancer therapy. Oncol Rev. 2017 Sep 15;11(2):341.
  • Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck. Head Neck. 2018 Jan;40(1):55-62.
  • Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy.
    LUNG CANCER 136/ :30-36,2019
  • Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
    ANNALS OF ONCOLOGY 30/7 :1,104-1,113,2019
  • Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 84/2 :405-414,2019
  • A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs.
    LUNG CANCER 134/ :46-51,2019
  • Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 145/6 :1,613-1,623,2019
  • YH25448, an irreversible EGFR-TKI with Potent Intracranial Activity in EGFR mutant non-smallcell lung cancer
    CLINICAL CANCER RESEARCH 25/8 :2,575-2,587,2019
  • Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma.
    LUNG CANCER 131/ :139-146,2019
  • Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
    YONSEI MEDICAL JOURNAL 60/6 :525-534,2019
  • Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate
    PLOS ONE 14/3 :e0214291-,2019
  • ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
    ONCOGENE 37/3 :377-388,2018
  • Characteristics and Outcome of ROS1-Positive Non?Small Cell Lung Cancer Patients in Routine Clinical Practice
    JOURNAL OF THORACIC ONCOLOGY 13/9 :1,373-1,382,2018
  • Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors.
    CANCER RESEARCH 78/12 :3,350-3,362,2018
  • Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
    LUNG CANCER 124/ :168-178,2018
  • Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival
    LUNG CANCER 121/ :12-17,2018
  • Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK 40/1 :55-62,2018
  • Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization.
    ONCOTARGET 8/50 :87,234-87,243,2017
  • Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis.
    ONCOTARGET 8/39 :65,111-65,122,2017
  • Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.
    ANNALS OF ONCOLOGY 28/6 :1,250-1,259,2017
  • PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
    SCIENTIFIC REPORTS 6/36956 :1-12,2016
  • Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 74/4 :799-808,2014
  • Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles
    ONCOLOGY 80/5-6 :395-405,2011
  • Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 66/4 :797-805,2010
  • Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II Trials
    Cancer Research And Treatment 41/4 :196-204,2009
  • clinical value of ezrin expression in primary osteosarcoma
    Cancer Research And Treatment 41/3 :138-144,2009
  • Prognosis of pN3 stage gastric cancer
    Cancer Research And Treatment 41/2 :73-79,2009
  • Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in korea
    Cancer Research And Treatment 41/2 :67-72,2009

홍민희

콘텐츠 처음으로 이동

네크워크 링크안내/사이트 정보